US88322Q1085
US88322Q1085
TG Therapeutics, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 8.48B EUR | 8.41B EUR | 5.09B EUR | 4.63B EUR |
Enterprise Value | 7.77B EUR | 8.68B EUR | 5.4B EUR | 4.8B EUR |
Valuation Multiples | ||||
Trailing P/E | 20.13x | 19.05x | 11.01x | 10.47x |
Forward P/E | 20.45x | -- | -- | -- |
Price to Sales | 10.6x | 10.52x | 7.26x | 9.34x |
Price to Book | 13.46x | 13.92x | 8.72x | 7.14x |
EV/Revenue | 9.72x | 10.86x | 7.71x | 9.7x |
EV/EBITDA | 56.93x | 58.45x | 33.87x | 39.35x |
Price to FCF (P/FCF) | 143.32x | 483.76x | -- | 1,233.26x |
EV/FCF | 131.37x | 499.39x | -- | 1,279.76x |
FCF Yield | 0.7% | 0.21% | -0.28% | 0.08% |